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Abstract 
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a 
chronic and economically significant respiratory disease that affects swine production 
worldwide. M. hyopneumoniae adheres to, and adversely affects the function of ciliated 
epithelial cells of the respiratory tract, and the cilium adhesin (P97), is intricately but not 
exclusively involved in this process. Although binding of pathogenic bacteria to 
glycosaminoglycans is a recognised step in pathogenesis, knowledge of 
glycosaminoglycan-binding proteins is lacking in M. hyopneumoniae. However, heparin 
and other sulfated polysaccharides are known to block the binding of M. hyopneumoniae 
to purified swine respiratory cilia. In this study, four regions within the cilium adhesin 
were examined for their ability to bind heparin. Cilium adhesin fragments comprising 
653 amino acids of the N- terminus and 301 amino acids of the C-terminus (containing 
two repeat regions, R1 and R2) were cloned and expressed. These fragments bound 
heparin in a dose-dependent and saturable manner with physiologically significant 
binding affinities of 0.27±0.02 µM and 1.89±0.33 µM, respectively. Heparin binding of 
both fragments was strongly inhibited by the sulfated polysaccharides fucoidan and 
mucin but not by chondroitin sulfate B. When the C-terminal repeat regions R1 and R2 
were cloned separately and expressed, heparin-binding activity was lost, suggesting that 
both regions are required for heparin binding. The ability of the cilium adhesin to bind 
heparin indicates that this molecule plays a multi-functional role in the adherence of M. 
hyopneumoniae to host respiratory surfaces and therefore has important implications with 
respect to the pathogenesis of this organism. 
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Introduction 
Mycoplasma hyopneumoniae is the aetiological agent of porcine enzootic pneumonia, 
a chronic respiratory disease that causes significant economic losses to the swine industry 
(30). Infections are established via colonization of porcine respiratory epithelia, a process 
initiated by the adherence of bacterial cells to host cilia. Successful colonization results in 
ciliostasis and shedding of cilia from the epithelial surface, thereby disrupting the muco-
ciliary escalator and leaving the host susceptible to secondary infections (3, 9).  
Studies have shown that the cilium adhesin, P97, is essential for the adherence of M. 
hyopneumoniae and the onset of disease (15, 37). The cilium adhesin gene encodes a 126 
kDa pre-protein. The full length protein is not present in in vitro grown cells in detectable 
amounts due to post-translational processing. A major cleavage event at position 195 
generates the functional adhesin (P97) and the N-terminal fragment (P22). P97 is further 
cleaved to yield a host of other peptides (10). While the functions of these peptides (apart 
from P97) are unknown, proteomic and immunogold studies demonstrate that they 
remain associated with the cell surface or the surrounding matrix (10).  
Like several other characterized mycoplasma adhesins, P97 contains repetitive 
elements within the C-terminal portion of its amino acid sequence (4, 8, 15). P97 contains 
two such repeat regions, designated R1 and R2, with R1 (sequence AAKPV/E) being 
identified as the cilium binding epitope (16). Size variation in the cilium adhesin protein 
of different M. hyopneumoniae strains (95-97 kDa) has been accounted for by differences 
in the number of copies of R1, which varies from 9 in the non-adherent J strain, to 15 in 
the pathogenic 232 strain (35). A minimum of 8 copies of the R1 repeat are necessary for 
cilial binding, but this is not sufficient to confer the ability to adhere in vivo (16, 23). 
 4 
These data suggest that there are additional proteins and mechanisms involved in 
adherence to host epithelia.  
The importance of binding to host extracellular matrix (ECM) components in 
initiating pathogenic processes has been well documented. By binding to ECM proteins 
such as fibronectin, vitronectin, laminin, and collagen, pathogenic microbes are able to 
mediate interactions with host cells (27), and in some cases enhance their invasive 
potential (12, 18, 28). Furthermore, it has been demonstrated that many pathogens are 
able to recruit exogenous glycosaminoglycans (eg. heparin, heparan sulfate and 
chondroitin sulfate B) to their surfaces to facilitate interactions between the pathogen and 
host ECM components, which are themselves glycosaminoglycan binding proteins (13, 
21, 34). Binding to glycosaminoglycans is also believed to enable pathogenic bacteria to 
evade the host immune system (7, 12) and modulate the inflammatory response (13) by 
allowing bridging interactions with host chemokines and cytokines. Thus, 
glycosaminoglycan-binding proteins are considered to be of central importance to the 
infection process.  
Previous experiments have revealed that adherence of purified recombinant P97 to 
cilia is inhibited by sulfated glycosaminoglycans (15). These findings suggest a possible 
interaction between the P97 protein and sulfated glycosaminoglycans which may act as 
receptor analogs for the M. hyopneumoniae adhesin (15, 36, 38); however; these studies 
did not directly demonstrate such an interaction. Furthermore, the domains within the 
cilium adhesin responsible for this interaction were not identified. In this study we 
identify regions within the cilium adhesin that interact with the glycosaminoglycan, 
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heparin. The ability of M. hyopneumoniae cell surface molecules to bind heparin may 
play a significant role in the pathogenesis of this organism.  
 
Materials and Methods 
Bacterial strains and plasmids. M. hyopneumoniae strain J (NCTC 10110) was 
cultivated to mid-log phase (medium pH range 6.8-7.2) in modified Friis broth at 37°C 
on a rotary shaker as described previously (33). The Escherichia coli plasmid expression 
and maintenance strains were M15 (pREP4) and JM109 respectively, and were grown in 
Luria-Bertani (LB) medium (31) at 37°C. Broth cultures were incubated on a rotary 
shaker at 200-250 rpm to achieve aeration. For selection of transformants, LB medium 
was supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin as required.  
DNA extraction. Chromosomal DNA was extracted from the J strain of M. 
hyopneumoniae using a phenol/chloroform method followed by dialysis against TE 
buffer as described previously (11). Plasmid DNA was extracted from E. coli using either 
the Qiagen mini-prep or midi-prep kit according to the manufacturer’s instructions 
(Qiagen, Alameda, Calif.).  
Plasmid constructs. Adhesin molecules from two different strains of M. 
hyopneumoniae were used to generate poly-histidine fusion proteins of different regions 
of the coding sequence. Because UGA codons encode tryptophan in mycoplasmas, they 
cause translation problems in E. coli, resulting in premature stops during expression of 
cloned sequences. To circumvent this problem, three clones were generated by 
amplifying chromosomal DNA from strain J, with PCR primers designed to avoid in-
frame TGA codons.  An additional construct was generated using a clone containing a 
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large fragment of the P97 sequence from strain P5722 (19) in which the TGA codons had 
been mutagenized to TGGs.  This approach was deemed valid because the sequence 
differences between these two P97 homologs is less than 4%, with most of the 
differences accounted for by variation in the number of R1 and R2 repeats.  
The first construct contained the region coding for the N-terminus of the cilium 
adhesin (amino acids 106-758 of mutagenized gene sequence) and was referred to as 
F1P97. The PCR template for this construct was pISM405 in which the TGA codons had 
been converted to TGGs (10). The second construct, referred to as F2P97 (amino acids 
768-1069 of J strain sequence), contained the cilium adhesin repeat domains coding for 
both R1, the cilium binding epitope, and R2. This gene fragment was further subcloned to 
yield two additional constructs referred to as F3P97 (amino acids 768-914 of J strain 
sequence) and F4P97 (amino acids 935-1069 of J strain sequence), which contained the R1 
and R2 regions, respectively (Fig. 1).  
To clone specific sequences, gene fragments were amplified via PCR using Taq 
polymerase (Qiagen). Primers used for the amplification of the gene fragments encoding 
F1P97, F3P97 and F4P97 were as follows: F1F (5’-GGGGATCCCAAGATCCTGAATAT 
ACC) and F1R (5’- GGCTGCAGTTAGGCTGCTTTAAGGAAAAATGC) (underlined 
sequences represent BamHI and PstI restriction sites, respectively); F3F (5’- GGGT 
CGACAAATTAGACGATAATCTTCAG) and F3R (5’- GGCTGCAGTTAC 
TCGCTTTGATGAACTAGTTC) (underlined sequences represent SalI and PstI 
restriction sites, respectively); F4F (5’- GGGGATCCCAGGAAGTCAAGGTAACT 
AGT) and F4R (5’- GGCTGCAGCCCGGGTTAGGATCACCGGATTTTGAATC) 
(underlined sequences represent BamHI and PstI restriction sites, respectively). Primers 
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F3F and F4R were used to amplify the gene fragment corresponding to F2P97. The F1P97-
F4P97 cilium adhesin fragments were digested with the appropriate restriction enzymes 
and ligated into linearized pQE-9 with 1 U of T4 DNA ligase (Roche, Basel, Switzerland) 
at 10°C overnight. Ligated plasmids were electroporated into E. coli M15 (pREP4) cells 
using a BioRad Gene Pulser (Bio-Rad Laboratories, Hercules, Calif.) at 2.5 kV, 25 µFD 
and 200 Ω according to the manufacturer’s instructions. All plasmid constructs were 
confirmed via DNA sequencing.  
Protein expression and purification. All cilium adhesin fragments were expressed 
as hexahistidyl fusion proteins and purified by nickel affinity chromatography. Briefly, E. 
coli M15 (pREP4) cells were grown to mid-log phase and induced with a final 
concentration of isopropyl-β-D-thiogalactopyranoside of 1 mM. Cells were harvested by 
centrifugation (4000 x g for 20 min) and then lysed in 8 M urea buffer (8 M urea, 0.01 M 
Tris, 0.1 M NaH2PO4; pH 8.0) with gentle rocking for 1 h. Cell debris was pelleted by 
centrifugation at 10,000 x g for 30 min. To the supernatant, 0.25 volumes of 50% Ni-
NTA slurry (Qiagen) was added and the solution allowed to mix gently for 1 h. The 
solution was loaded onto a glass column and washed twice with 8M urea buffer (pH 6.3) 
to remove unbound protein. Bound protein was eluted with low pH urea buffers (pH 5.9 
and pH 4.5). Proteins were analysed for purity using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) then dialysed for 48 h with multiple 
buffer changes against phosphate buffered saline (PBS; 10 mM sodium phosphate – 150 
mM sodium chloride, pH 7.4)-0.1% SDS or PBS-5% glycerol to remove the urea. The 
concentration of the purified proteins was estimated using the Bradford assay (Bio-Rad 
Laboratories). 
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Production of polyclonal antisera. Antisera to the F1P97-F4P97 adhesin fragments 
were generated via primary and secondary intramuscular injections of antigen into New 
Zealand white rabbits at two-week intervals. Antigens (approximately 0.5 mg) were 
prepared for injection by mixing equal volumes of purified protein (approximately 500 
µl) and Freund’s Incomplete Adjuvant (Sigma Aldrich, St. Louis, Missouri). Pre-immune 
serum was collected prior to the primary injection and served as control antiserum. A trial 
bleed was performed 10-14 days after the secondary injection of antigen and immune 
responses to the antigen at this stage were assessed via immunoblotting. Positive sera 
were collected via cardiac bleed during which the rabbits were anaesthetized and 
euthanized as previously described (32). 
Heparin binding assays. For ligand dot blot assays, purified proteins were diluted to 
5 µg/ml in PBS. To denature samples, proteins were diluted in electrophoresis sample 
buffer (60 mM Tris pH 6.8, 1% SDS, 1% β-mercaptoethanol, 10% glycerol, 0.01% 
bromophenol blue) and boiled for 5 min. A 100 µl volume of each sample was spotted 
onto a Hybond-C super nitrocellulose membrane (Amersham Pharmacia Biotech, 
Uppsala, Sweden) that had been pre-wetted in Tris-buffered saline (TBS; 10 mM Tris, 
150 mM sodium chloride; pH 7.4) using a Bio-Dot Microfiltration Apparatus (Bio-Rad 
Laboratories). The membrane was blocked with 300 µl per well of blocking solution (1% 
bovine serum albumin (BSA) in TBS) and then washed twice under vacuum with 300 µl 
per well of TTBS wash solution (0.05% Tween 20 in TBS). The membrane was removed 
from the manifold and placed in a dish containing 100 µg/ml biotinylated heparin 
(Sigma) diluted in 1% BSA-TTBS. The membrane was incubated for 1 h with gentle 
rocking and was then washed 3 x 10 min in TTBS. Streptavidin peroxidase (Roche) was 
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diluted 1:3000 in 1% BSA-TTBS and added to the membrane. After 1 h incubation the 
blot was washed 3 x 10 min with TTBS. The membrane was equilibrated with 100 mM 
Tris (pH 7.6) and developed with 3,3’-diaminobenzidine (Sigma) solution. 
For microtitre plate binding assays, 96 well plates (Linbro/Titertek; ICN Biomedicals 
Inc., Aurora, Ohio) were coated overnight in a humidified chamber with 0.5 µg per well 
purified protein diluted in 100 µl carbonate coating buffer (18 mM NaHCO3, 27 mM 
Na2CO3; pH 9.5). Following overnight incubation, the plates were washed 5 times with 
PBS-0.2% Tween 20 (200 µl wash solution per well) using an automatic 96PW plate 
washer (SLT Labinstruments, Crailsheim, Germany). The wells were blocked with 100 
µl of blocking solution (2% skim milk in PBS) for 1 h in a humidified chamber. The 
plates were washed 5 times and biotinylated heparin which had been pre-diluted in 1% 
skim milk-PBS was added in increasing concentrations to the wells. Final concentrations 
of biotinylated heparin were 0, 1, 5, 10, 20, 50, and 100 µg/ml. Aliquots of 100 µl of each 
concentration were added to microtitre plate wells; the plates were then incubated for 1 h. 
After washing the plates as above, 100 µl of streptavidin-peroxidase (Roche) diluted 
1:3000 in 1% skim milk-PBS was added to each well and incubated for 1 h. The plates 
were washed and developed using 1 mM 2, 2’-azino-bis (3-ethylbenzothiazoline-6-
sulfonic acid) substrate (Sigma) in citrate buffer (100 mM citric acid, 200 mM Na2HPO4, 
pH 4.2) which had been activated with hydrogen peroxide. Plates were developed with 
shaking on a Titramax 1000 microtitre plate shaker (Heidolph, Schwabach, Germany), 
and the optical density at 414 nm measured with a Multiskan Ascent plate reader 
(Thermo Labsystems, Franklin, Mass.) at 7, 15, 25 and 45 min intervals.  
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Microtitre plate assays for determining the specificity of heparin binding, were 
performed as above but with serial 2-fold dilutions of biotinylated heparin, beginning at 
saturating concentration (100 µg/ml for F1P97 and 50 µg/ml for F2P97), each of which 
were pre-mixed with a 50-fold excess of unlabelled heparin prior to addition to the plates. 
Competitive binding assays were also performed as above but with the addition of a 
1, 5, 10, 20, 30, 40 and 50-fold excess of a range of sulfated polysaccharides. Inhibitors 
were pre-mixed with biotinylated heparin immediately prior to addition to the wells and 
included unlabelled heparin, fucoidan, mucin and chondroitin sulfate B (Sigma). In all 
microtitre plate assays, controls were performed in uncoated wells, wells where no 
heparin was added, or wells where no streptavidin-peroxidase was added. Controls which 
employed protein-specific antiserum and horseradish peroxidase (HRP)-labelled anti-
rabbit IgG (Chemicon, Temecula, Calif.) were also conducted to ensure that proteins 
were adhering to the microtitre plate wells. All experiments were performed in triplicate. 
Results were graphed with GraphPad Prism version 4.02 for Windows (GraphPad 
Software, San Diego, Calif.; www.graphpad.com) using non-linear regression. 
 
Results 
Bioinformatic identification of putative heparin binding motifs. The cilium 
adhesin was examined for potential heparin-binding sites within its amino acid sequence 
using established criteria (5, 6). In many instances, glycosaminoglycan binding proteins 
are reported to contain consensus sequences of two types: XBBXBX and XBBBXXBX, 
where B represents a basic residue and X any other amino acid. The F1P97 and F2P97/F3P97 
domains of the cilium adhesin each contain one motif that matches the former consensus 
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sequence (DKKDKS and DKKVKE respectively) (Fig. 2). Several heparin binding 
proteins have been identified that do not contain the consensus sequences but possess 
sequences that are relatively rich in basic residues (20, 29). Both F1P97 and F2P97 also 
contain relatively large numbers of basic amino acids across the length of their sequences 
(Fig. 2).  
Heparin binding assays. To determine whether the cilium adhesin fragments bound 
to heparin and to assess the importance of their protein conformation in this process, 
ligand blots were performed. Standard ligand blots involving the transfer of proteins from 
denaturing polyacrylamide gels to PVDF gave only weak or unreliable results (data not 
shown). In a dot blot assay, strong and reproducible reactions with biotinylated heparin 
were observed for undenatured F1P97 and F2P97, while a weak reaction was observed for 
undenatured F4P97 (Fig. 3). Interestingly, the same protein fragments did not show a 
strong reaction with heparin when they were denatured prior to blotting, indicating that 
protein conformation may play a role in the interaction with heparin. 
Quantification of heparin binding by the cilium adhesin domains and determination of 
binding affinities was performed by a microtiter plate binding assay. The recombinant 
cilium adhesin fragments F1P97-F4P97 were shown to reliably bind to microtitre plates by 
interacting with fragment-specific antibodies (data not shown). Experiments were then 
performed with increasing amounts of biotinylated heparin up to a saturating 
concentration. Fig. 4 indicates the total binding (specific and non-specific) of the cilium 
adhesin fragments to heparin. Both F1P97 and F2P97 were found to bind heparin in a dose-
dependent and saturable manner. In contrast, F3P97 and F4P97 showed low-level, non-
saturable binding, indicating a non-specific interaction.  
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To determine whether the binding of F1P97 and F2P97 to heparin was the result of a 
specific interaction, binding assays were undertaken in which biotinylated heparin was 
added in the presence and absence of a 50-fold concentration of unlabelled heparin. 
Binding of heparin to both F1P97 and F2P97 was shown to be highly specific with minimal 
non-specific binding observed (Fig. 5A and 5B). Affinity constants were determined 
using the specific binding data (total binding minus non-specific binding) and were found 
to be 0.27±0.02 µM and 1.89±0.33 µM for F1P97 and F2P97, respectively. These values are 
comparable to those derived from replicate experiments. 
Inhibition of heparin binding using sulfated polysaccharides. The nature of the 
interaction between the cilium adhesin fragments and heparin was further characterised in 
competitive binding experiments using the sulfated polysaccharides heparin, fucoidan, 
mucin and chondroitin sulfate B. For both F1P97 and F2P97, biotinylated heparin binding 
was significantly inhibited by heparin. Furthermore, for both F1P97 and F2P97, fucoidan 
and mucin were shown to be strong competitors while chondroitin sulfate B did not 
inhibit the interaction of heparin with either adhesin domain (Fig. 6A and 6B). Notably, 
both fucoidan and mucin gave stronger inhibition than unlabelled heparin. These results 
suggest that both F1P97 and F2P97 are able to bind fucoidan and mucin in addition to 
heparin.  
 
Discussion 
In order to establish infection, bacterial pathogens must first adhere to and colonize 
host epithelia. For many bacteria, the initial site of contact with host tissues is at the level 
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of the ECM, therefore the ability to bind components of the ECM is widespread amongst 
pathogenic microbes (12, 13, 22, 34). Because of their fastidious nature and obligate 
parasitic mode of life, mycoplasmas require particularly efficient mechanisms for 
adherence. For M. hyopneumoniae, knowledge about the mechanisms of adhesion to host 
tissues is currently confined to the cilium adhesin and its interaction with the cilia of the 
porcine respiratory tract (15, 17, 23, 37). No ECM-binding proteins have been identified 
in this organism; however, previous studies indicated that binding of the cilium adhesin 
to cilia could be inhibited by heparin, providing indirect evidence that the adhesin is able 
to bind this molecule (15, 38).  
In this study, two non-overlapping regions of the M. hyopneumoniae cilium adhesin, 
F1P97 and F2P97, were shown to bind heparin in a dose-dependent, saturable manner. 
These results indicate that there are at least two distinct heparin-binding domains within 
the adhesin protein. Both of these regions contain clusters of basic amino acids that 
match the consensus for glycosaminoglycan-binding motifs (6). One of these protein 
regions, F2P97, contains both of the cilium adhesin repeat regions, R1 and R2. The 
heparin-binding consensus motif of F2P97 lies within the F3P97 region (Fig. 1A), which 
would suggest that F3P97 should also bind heparin. As F3P97 was not shown to bind 
heparin in either the ligand blot or microtitre plate assay, it must be concluded that the 
heparin binding motif in F2P97 alone was not sufficient to confer binding activity, 
indicating that additional sequences are required. F4P97 also failed to show any significant 
interaction with heparin in microtitre plate assays indicating that while R1 and R2 are 
unable to bind heparin independently, the intact F2P97 fragment (containing both of these 
regions) displays heparin-binding activity. The fact that both of the cilium adhesin repeat 
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regions are required for heparin binding suggests that this interaction is conformation-
dependent rather than due to the presence of a specific linear amino acid motif. 
Furthermore, the idea that protein conformation plays a role in heparin-binding is 
supported by the ligand blot data which demonstrated that undenatured F1P97 and F2P97 
were able to bind heparin while the denatured forms were unable to do so.  
Alternatively, since 20 amino acids (914-935) were omitted during the construction of 
F3P97 and F4P97, it is possible that this sequence may be responsible for the heparin-
binding activity observed for F2P97. However, an analysis of this sequence failed to 
identify a heparin-binding motif or a basic amino acid density that might facilitate 
binding.  
Studies on the proteolytic cleavage of the M. hyopneumoniae cilium adhesin have 
revealed a complex processing pattern. One major processing event cleaves an N-
terminal 22 kDa fragment (P22), generating the “mature” P97 adhesin (10, 37). A second 
major event (at position 862 for the J strain) removes a C-terminal 28 kDa fragment 
(P28) that separates the cilium binding epitope, R1, from R2. This event generates a 
central adhesin fragment that contains R1 and is approximately 66 kDa in size (P66) (10). 
Since both R1 and R2 are necessary for the F2P97 fragment of the adhesin to bind heparin, 
the cleavage event that generates P28 is likely to impact on the ability of some cilium 
adhesin cleavage products to bind glycosaminoglycans. However, this cleavage event 
may not have a detrimental effect on the ability of P66 to bind heparin since this is likely 
to be conferred by the second heparin binding site found in F1P97. The presence of two 
distally located heparin binding sites may allow M. hyopneumoniae to alter its surface 
architecture without a corresponding loss in heparin binding activity.  
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For some proteins, the ability to bind heparin has been attributed to the presence of 
relatively high numbers of evenly spaced basic amino acid residues rather than the 
presence of specific linear motifs (20, 29). The positively-charged basic residues are 
believed to interact with the exposed, negatively-charged sulfate groups of heparin and 
other glycosaminoglycans (5, 6, 20). This may also be true of the cilium adhesin regions 
F1P97 and F2P97 which are relatively rich in lysine residues. Further evidence for this type 
of interaction can be derived from competitive binding assays. Binding of both F1P97 and 
F2P97 to heparin was disrupted by the addition of fucoidan, a highly sulfated fucose 
polymer derived from marine algae, but not by chondroitin sulfate B. While not present 
in mammalian systems, fucoidan is useful in binding studies due to the high degree of 
sulfation of its carbohydrate chains and for this reason is frequently found to be a potent 
inhibitor of protein-heparin interactions (14, 24). The strong inhibition of heparin binding 
by fucoidan highlights the significance of sulfate groups in this interaction.  
Mucin, another highly sulfated compound, was also found to be a powerful inhibitor 
in our competitive binding assays. Mucins are abundant in the mucosal secretions lining 
various epithelial surfaces (25). Thus, the ability of the cilium adhesin fragments to bind 
mucin may in itself be highly significant, since the mucosal layer is often considered the 
first defense against pathogens that colonize epithelial surfaces (1). Interactions with the 
mucous layer of the respiratory tract would likely precede binding of M. hyopneumoniae 
to cilia; therefore binding to mucins may represent an important first step in the 
pathogenesis of this organism. Further studies are required to characterize this 
interaction. 
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The binding affinities (Kd) of both F1P97 (0.27 ± 0.02 µM) and F2P97 (1.89 ± 0.33 µM) 
for heparin are within the range reported for other heparin-binding proteins (0.3 nM - 4 
µM) such as antithrombin (2), interleukins 2 and 12 (14, 24), clusterin (26) and the 
mycobacterial heparin-binding haemagglutinin (29), suggesting that these interactions are 
of physiological significance. The ability of the M. hyopneumoniae cilium adhesin to 
bind to components of the ECM as well as to cilia indicates that this molecule plays a 
multi-functional role in adherence to the porcine respiratory tract. While more 
experiments are required to establish the precise role of the adhesin’s interaction with 
glycosaminoglycans in vivo, studies of microbial pathogenesis continue to highlight the 
importance of binding to heparin and other sulfated polysaccharides in the establishment, 
maintenance and dissemination of infection (13, 21, 27, 34). Many pathogens, including 
Neisseria, Yersinia, and Staphylococcus species, exploit the widespread ability of host 
proteins to bind heparin. By recruiting heparin to their surfaces, these organisms acquire 
the ability to interact with a multitude of host molecules and circumvent the need for 
individual ligand receptors (13). For organisms such as M. hyopneumoniae, which have 
small genomes and therefore a limited repertoire of proteins, the ability to bind 
exogenous heparin may significantly increase the potential for host-parasite interactions 
at the site of colonization. Host molecules known to interact with heparin include ECM 
components, such as fibronectin and vitronectin, and cytokines and inflammatory 
mediators (13). Thus, the ability of M. hyopneumoniae to bind heparin may have 
important implications with respect to modulation of the host immune system and 
inflammatory response in addition to adherence of the pathogen to host tissues.  
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Figure legends 
Figure 1.  (A)  Diagrammatic representation of the cilium adhesin gene.  Arrows indicate 
the location of primers used to amplify DNA fragments coding for F1P97-F4P97. Amino 
acid positions corresponding to the N- and C-termini of F1P97-F4P97 are indicated.  
Numbers marked with an asterisk (*) indicate positions corresponding to the cilium 
adhesin of M. hyopneumoniae strain P5722; all other numbers correspond to the cilium 
adhesin M. hyopneumoniae strain J.  The F1P97-F4P97 adhesin fragment sizes are 
indicated. (B)  Sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) showing the 
purified, recombinant F1P97-F4P97 cilium adhesin fragments.  Lane 1:  Prestained protein 
molecular weight marker (MBI Fermentas, Hanover, Maryland);  band sizes correspond 
to 118, 86, 47, 34, 26 and 19kDa, Lane 2:  F1P97, Lane 3:  F2P97, Lane 4: F3P97, Lane 5:  
F4P97.  All cilium adhesin fragments run at higher molecular weights than predicted due 
to abnormal migration patterns. 
 
Figure 2.  Amino acid sequences of F1P97-F4P97.  The sequences shown correspond to the 
M. hyopneumoniae strains and numbering described in Fig 1A.  F3P97 and F4P97 are 
indicated by large boxes.  Small boxes indicate motifs matching the heparin-binding 
consensus sequences. Basic residues are shaded.  Tryptophan residues that represent 
mutagenised TGG codons are underlined.  Repeat regions 1 and 2 (R1 and R2) are 
italicized and underscored. 
 
Figure 3.   Ligand dot blot of denatured and undenatured cilium adhesin fragments 
reacted with (A) biotinylated heparin and (B) amido black.  All samples were analysed on 
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a single blot.  Position 1: undenatured F1P97; position 2: denatured F1P97; position 3: 
undenatured F2P97, position 4: denatured F2P97, position 5: undenatured F3P97, position 6: 
denatured F3P97, position 7: undenatured F4P97, position 8: denatured F4P97.   
 
Figure 4.  Binding of biotinylated heparin to immobilized cilium adhesin domains F1P97 
(●), F2P97 (○), F3P97 (■) and F4P97 (□).  Increasing concentrations of biotinylated heparin 
were added until saturation was reached.  Absorbances were read after 45 min incubation 
in the presence of substrate.  Error bars indicate the standard deviation from the mean for 
triplicate readings.  Replicate experiments resulted in similar binding curves.   
 
Figure 5.   Heparin binding curves for (A) F1P97 and (B) F2P97 showing total binding (●), 
non-specific binding (■) and specific binding (○).  Total binding was determined using 
the standard microtitre plate assay protocol while non-specific binding was determined in 
the presence of a 50-fold excess of unlabelled heparin.  The specific binding curves were 
derived by subtracting the non-specific binding data from the total binding data.  Error 
bars indicate the standard deviation from the mean for triplicate readings. 
 
Figure 6.  Competitive binding assays showing inhibition of heparin binding to (A) F1P97 
and (B) F2P97 by various sulfated polysaccharides:  unlabelled heparin (●), fucoidan (■), 
mucin (○) and chondroitin sulfate B (□).  Microtitre plate binding assays were performed 
using the standard protocol but with an excess of each inhibitor.  Error bars indicate the 
standard deviation from the mean for triplicate readings. 
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Figure 2. 
 
F1P97                                                                                                  
 
QDPEYTKAKITFEILEIIPDDVNQNFKVKFQALQKLHNGDIAKSDIYEQT                                           
VAFAKQSNLLVAEFNFSLKKITEKLNQQIENLSTKITNFADEKTSSQKDP                                                                                                                    
STLRAIDFQYDLNTARNPEDLDIKLANYFPVLKNLINRLNNAPENKLPNN                                                                                                                                                    
LGNIFKFSFAKDSSTNQYVSIQNQIPSLFLKADLSQSAREILASPDEVQP                                                                                                                                                    
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NYLPELGKKIDEIIKKQGKNWKTEVELIEDNIAGDAKLLYFVLRDDSKSG                                               
DP 
 
 
 
 
 
 
 
 
 
 
F4
P97 
F3
P97 
 27 
 
Figure 3. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8
A
B
 28 
 
 
 
Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
0 25 50 75 100
0
1
2
3
4
5
6
[Biotinylated Heparin] (µg/mL)
O
p
ti
c
a
l 
D
e
n
s
it
y
(4
1
4
n
m
)
 29 
 
Figure 5A. 
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